User profiles for Germán Áñez
 | Germán Añez, MD, FIDSAExecutive Director/Distinguished Scientist, PDTL, Vaccine Clinical Research, MRL - Merck & … Verified email at merck.com Cited by 1848 |
[HTML][HTML] Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico
Background NVX-CoV2373 is an adjuvanted, recombinant spike protein nanoparticle vaccine
that was shown to have clinical efficacy for the prevention of coronavirus disease 2019 (…
that was shown to have clinical efficacy for the prevention of coronavirus disease 2019 (…
[HTML][HTML] Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial
In the PREVENT-19 phase 3 trial of the NVX-CoV2373 vaccine (NCT04611802), anti-spike
binding IgG concentration (spike IgG), anti-RBD binding IgG concentration (RBD IgG), and …
binding IgG concentration (spike IgG), anti-RBD binding IgG concentration (RBD IgG), and …
[PDF][PDF] Impacto económico del dengue y del dengue hemorrágico en el Estado de Zulia, Venezuela, 1997-2003
OBJETIVOS: Determinar los costos directos e indirectos asociados con la atención de los
casos de dengue y de dengue hemorrágico o síndrome de choque por dengue (DH/SCD) …
casos de dengue y de dengue hemorrágico o síndrome de choque por dengue (DH/SCD) …
Safety, immunogenicity, and efficacy of the NVX-CoV2373 COVID-19 vaccine in adolescents: a randomized clinical trial
Importance Greater than 20% of cases and 0.4% of deaths from COVID-19 occur in children.
Following demonstration of the safety and efficacy of the adjuvanted, recombinant spike …
Following demonstration of the safety and efficacy of the adjuvanted, recombinant spike …
[HTML][HTML] Alteraciones hepáticas en pacientes con dengue
…, LM Espina, J Arias, E Meleán, G Añez… - Investigación …, 2005 - ve.scielo.org
La caracterización clínica del Dengue es muy variable debido a las múltiples alteraciones
inducidas por el virus en el organismo. Se ha reportado incremento en los niveles de …
inducidas por el virus en el organismo. Se ha reportado incremento en los niveles de …
Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine
…, A McGarry, W Woo, I Cho, K Alves, G Áñez… - Expert Review of …, 2023 - Taylor & Francis
Introduction The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in significant morbidity and …
respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in significant morbidity and …
[HTML][HTML] Epidemiological scenario of dengue in Brazil
Dengue is the most important reemerging mosquito-borne viral disease worldwide. It is
caused by any of four Dengue virus types or serotypes (DENV-1 to DENV-4) and is transmitted …
caused by any of four Dengue virus types or serotypes (DENV-1 to DENV-4) and is transmitted …
Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III …
G Áñez, J Hedrick, MW Simon… - Human Vaccines & …, 2020 - Taylor & Francis
The quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) was
assessed as a booster in this Phase III trial (NCT02752906). Quadrivalent meningococcal …
assessed as a booster in this Phase III trial (NCT02752906). Quadrivalent meningococcal …
[HTML][HTML] NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial
…, W Woo, A McGarry, H Beyhaghi, G Áñez… - Vaccine, 2023 - Elsevier
PREVENT-19, the pivotal phase 3 trial of the Novavax adjuvanted, recombinant spike protein
COVID-19 vaccine (NVX-CoV2373), demonstrated that the vaccine was well tolerated and …
COVID-19 vaccine (NVX-CoV2373), demonstrated that the vaccine was well tolerated and …
[HTML][HTML] Evolución molecular del virus dengue: un área de investigación prioritaria
G Áñez - Investigación Clínica, 2007 - ve.scielo.org
Esta en fer me dad se en cuen tra dis tribui da en gran par te de los paí ses tro pi ca les en de
sa rro llo, sien do en dé mi ca en mu chos de ellos, en los que pro du ce epi de mias en for …
sa rro llo, sien do en dé mi ca en mu chos de ellos, en los que pro du ce epi de mias en for …
